First in Man Clinical Study to Investigate Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of CM3.1-AC100

Inclusion Criteria: * Provision of signed and dated informed consent prior to any study specific procedures * Body weight between 60.0 to 100.0 kg (both inclusive) and BMI 19 to 29.9 kg/m2 (both inclusive) * Judged as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination) Exclusion Criteria: * Any history or presence of a clinically relevant disease as judged to be relevant by the Investigator * Blood donation within 3 month before administration of the IP * Have a history of hypersensitivity to the IP or any of the excipients or to medicinal products with similar chemical structures